Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant

HIV-1 is a chronic disease managed by strictly adhering to daily antiretroviral therapy (ART). However, not all people living with HIV-1 have access to ART, and those with access may not adhere to treatment regimens increasing viral load and disease progression. Here, a subcutaneous nanofluidic implant was used as a long-acting (LA) drug delivery platform to address these issues. The device was loaded with tenofovir alafenamide (TAF) and implanted in treatment-naïve simian HIV (SHIV)-positive nonhuman primates (NHP) for a month. We monitored intracellular tenofovir-diphosphate (TFV-DP) concentration in the target cells, peripheral blood mononuclear cells (PBMC). The concentrations of TFV-DP were maintained at a median of 391.0 fmol/106 cells (IQR, 243.0 to 509.0 fmol/106 cells) for the duration of the study. Further, we achieved drug penetration into lymphatic tissues, known for persistent HIV-1 replication. Moreover, we observed a first-phase viral load decay of −1.14 ± 0.81 log10 copies/mL (95% CI, −0.30 to −2.23 log10 copies/mL), similar to −1.08 log10 copies/mL decay observed in humans. Thus, LA TAF delivered from our nanofluidic implant had similar effects as oral TAF dosing with a lower dose, with potential as a platform for LA ART.

[1]  A. Grattoni,et al.  Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. , 2020, International journal of pharmaceutics.

[2]  A. Grattoni,et al.  Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody , 2020, Advanced Therapeutics.

[3]  A. Grattoni,et al.  Silicon Nanofluidic Membrane for Electrostatic Control of Drugs and Analytes Elution , 2020, Pharmaceutics.

[4]  M. Ferrari,et al.  Counteracting Muscle Atrophy on Earth and in Space via Nanofluidics Delivery of Formoterol , 2020 .

[5]  Jean A. Niles,et al.  Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates , 2020, bioRxiv.

[6]  A. Grattoni,et al.  Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery , 2020, Lab on a chip.

[7]  A. Pimpinelli,et al.  Finite-size charged species diffusion and pH change in nanochannels. , 2020, ACS applied materials & interfaces.

[8]  Saijuan Zhang,et al.  Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. , 2020, The lancet. HIV.

[9]  Study to Evaluate the Safety and Efficacy of GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance , 2019, Case Medical Research.

[10]  T. Brown,et al.  Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men , 2019, Journal of the International AIDS Society.

[11]  Ewa Bryndza Tfaily,et al.  A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques , 2019, Antimicrobial Agents and Chemotherapy.

[12]  A. Grattoni,et al.  2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[13]  A. van der Straten,et al.  Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP) , 2019, Pharmaceutics.

[14]  A. Grattoni,et al.  Remotely controlled nanofluidic implantable platform for tunable drug delivery. , 2019, Lab on a chip.

[15]  A. Ballerini,et al.  Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases , 2019, Biomedical Microdevices.

[16]  A. Ballerini,et al.  Nanofluidic microsystem for sustained intraocular delivery of therapeutics. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[17]  M. Ferrari,et al.  Gas Flow at the Ultra-nanoscale: Universal Predictive Model and Validation in Nanochannels of Ångstrom-Level Resolution. , 2018, ACS applied materials & interfaces.

[18]  R. L. Hood,et al.  Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre‐exposure prophylaxis , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[19]  E. B. Butler,et al.  Nanofluidic drug‐eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Marian E. Gindy,et al.  Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention , 2018, Antimicrobial Agents and Chemotherapy.

[21]  R. L. Hood,et al.  Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale , 2018, Nature Communications.

[22]  D. Podzamczer,et al.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial , 2017, The Lancet.

[23]  A. Ballerini,et al.  Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome , 2016, International Journal of Obesity.

[24]  Erica B. Schlesinger,et al.  A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis , 2016, Pharmaceutical Research.

[25]  Jingwei Shao,et al.  Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. , 2016, Nanomedicine.

[26]  Camille Dollinger,et al.  Macrophage responses to implants: prospects for personalized medicine , 2015, Journal of leukocyte biology.

[27]  Jingwei Shao,et al.  Systems Approach to targeted and long-acting HIV/AIDS therapy , 2015, Drug Delivery and Translational Research.

[28]  Silvia Ferrati,et al.  The nanochannel delivery system for constant testosterone replacement therapy. , 2015, The journal of sexual medicine.

[29]  Thomas J. Smith,et al.  Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis , 2015, Antimicrobial Agents and Chemotherapy.

[30]  William A. Lee,et al.  Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. , 2014, The Journal of antimicrobial chemotherapy.

[31]  J. Skarbinski,et al.  Discontinuation of Antiretroviral Therapy Among Adults Receiving HIV Care in the United States , 2014, Journal of acquired immune deficiency syndromes.

[32]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[33]  Mauro Ferrari,et al.  Leveraging nanochannels for universal, zero-order drug delivery in vivo. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[34]  S. Lewin,et al.  The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.

[35]  W. Spreen,et al.  Long-acting injectable antiretrovirals for HIV treatment and prevention , 2013, Current opinion in HIV and AIDS.

[36]  U. Bredeek,et al.  Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.

[37]  Stephen E. Saddow,et al.  Silicon carbide: a versatile material for biosensor applications , 2013, Biomedical Microdevices.

[38]  Peter L. Anderson,et al.  Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men , 2012, Science Translational Medicine.

[39]  Jiangang Du,et al.  Amorphous Silicon Carbide as a Non-Biofouling Structural Material for Biomedical Microdevices , 2012 .

[40]  Mauro Ferrari,et al.  Gated and near-surface diffusion of charged fullerenes in nanochannels. , 2011, ACS nano.

[41]  P. Anderson,et al.  Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. , 2011, Journal of pharmaceutical and biomedical analysis.

[42]  J. Allan,et al.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation , 2010, Retrovirology.

[43]  Mauro Ferrari,et al.  Analysis of a nanochanneled membrane structure through convective gas flow , 2009 .

[44]  J. Overbaugh,et al.  Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge , 2007, Journal of medical primatology.

[45]  B. Conway,et al.  The Role of Adherence to Antiretroviral Therapy in the Management of HIV Infection , 2007, Journal of acquired immune deficiency syndromes.

[46]  Stuart F Cogan,et al.  Plasma-enhanced chemical vapor deposited silicon carbide as an implantable dielectric coating. , 2003, Journal of biomedical materials research. Part A.

[47]  D. Dimitrov,et al.  Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy , 2001, The Lancet.

[48]  A. Perelson,et al.  Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy , 2001, Antimicrobial Agents and Chemotherapy.